XON - Intrexon Corporation
| Previous Close | 15.73 |
| Open | 15.75 |
| Bid | 14.60 x 4000 |
| Ask | 0.00 x 3100 |
| Day's Range | 14.99 - 15.80 |
| 52 Week Range | 10.26 - 25.88 |
| Volume | 8,279,350 |
| Avg. Volume | 1,248,223 |
| Market Cap | 2.005B |
| Beta | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.80 |
- ACCESSWIRE•4 days ago
Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
- PR Newswire•5 days ago
Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.
- PR Newswire•5 days ago
Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON) (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.
- CNBC•6 days ago
Cramer's lightning round: Medical device stocks tend to win big
Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.
- GlobeNewswire•6 days ago
Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
Ziopharm, Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch.
- Zacks•14 days ago
Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound?
Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•20 days ago
Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20 mg veledimex cohort who received ...
- Simply Wall St.•24 days ago
Does Intrexon Corporation’s (NYSE:XON) Latest Financial Perfomance Look Strong?
When Intrexon Corporation (NYSE:XON) released its most recent earnings update (31 March 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...
- PR Newswire•26 days ago
Isolation and Recombinant Expression of Key Enzyme for Opioid Production
Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers 20-fold in Engineered Yeast Strains BUDAPEST, Hungary , May 29, 2018 /PRNewswire/ ...
- PR Newswire•last month
Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly™ Mosquitoes Platform
Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation (XON), announced that the newest addition to its Friendly™ Aedes aegypti mosquito line, "OX5034", will initiate open field trials on May 23, 2018. OX5034 is the next generation of Oxitec's non-biting Friendly™ Aedes mosquitoes, designed to reduce populations of the disease-spreading Aedes aegypti mosquito. This first field trial of this second generation Friendly™ Aedes mosquito will take place in Indaiatuba, a municipality in the state of São Paulo and part of the metropolitan region of Campinas, Brazil.
- PR Newswire•last month
The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. (XON) announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.
- PR Newswire•last month
The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti
The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.
- PR Newswire•last month
Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. "This start of dosing is an exciting and important milestone for Precigen as INXN-4001 is the first investigational new drug (IND) application filed and the first patient dosed for Precigen as a newly formed wholly-owned subsidiary of Intrexon," said Helen Sabzevari, PhD, president of Precigen.
- GlobeNewswire•last month
Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers. -IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients ...
- GlobeNewswire•last month
Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H&R ...
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / While one biotech company went up, the other went down on Friday. Intrexon shares tanked on Friday over first quarter results that didn’t impress traders, as shares of Supernus Pharmaceuticals were galloping ahead on a strong first quarter report. Intrexon Corporation shares closed down almost 20% on Friday with a little over 5 million shares traded.
- PR Newswire•last month
Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
GERMANTOWN, Md. , May 14, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
- ACCESSWIRE•last month
Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks
Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.
- Thomson Reuters StreetEvents•last month
Edited Transcript of XON earnings conference call or presentation 10-May-18 9:30pm GMT
Q1 2018 Intrexon Corp Earnings Call
- Motley Fool•last month
Here's What's Causing Intrexon to Tumble 20% Today
The company's collaboration revenue took a big step backward in the first quarter.
- Zacks•last month
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Intrexon Corporation and Synergy Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...
- PR Newswire•last month
Intrexon Announces First Quarter 2018 Financial Results
- Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million - - Adjusted EBITDA of $(19.7) million - GERMANTOWN, Md. , ...
- GlobeNewswire•last month
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (ZIOP), today announced financial results for the first quarter ended March 31, 2018, and provided an update on the Company’s recent activities. “The landscapes of CAR-T therapies and the use of cytokines are playing out as anticipated,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. Dr. Cooper continued, “Immune-stimulatory cytokines have gained significant momentum as potential combination therapies with immune checkpoint inhibitors.
- CNBC Videos•6 days ago
Cramer's lightning round: Medical device stocks tend to w...
Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.
